 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
4-26-2021
Insider Buy |
Michael L. Meyers
SVP, Chief Medical Officer |
$15.46
CAGR »
|
$7,730.00
500 shares |
4-22-2021
Insider Buy |
Dennis Podlesak
|
$14.11
CAGR »
|
$197,077.16
13,967 shares |
5-13-2019
Insider Buy |
Briggs Morrison
Chief Executive Officer |
$7.46
CAGR »
|
$152,242.80
20,400 shares |
3-21-2019
Insider Buy |
Michael L. Meyers
SVP, Chief Medical Officer |
$4.87
CAGR »
|
$38.96
8 shares |
10-30-2018
Insider Buy |
Michael L. Meyers
SVP, Chief Medical Officer |
$4.79
CAGR »
|
$958.00
200 shares |
3-8-2016
Insider Buy |
Ivor Royston
Director |
$12.00
CAGR »
|
$1,800,000.00
150,000 shares |
Also See: Institutional Holders of SNDX
Also See: SEC filings
Below we present the annualized performance delivered by SNDX stock since 4-26-2021 (the date of the most recent
insider purchase). The performance of the investment from the time SNDX insider buying occurred is the ultimate
test of whether insiders were right about SNDX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/27/2021 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$16.26 |
|
| End price/share: |
$20.79 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
27.86% |
|
| Average Annual Total Return: |
8.55% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$12,784.81 |
|
| Years: |
2.99 |
|
SNDX Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent SNDX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding SNDX
|
|
Free SNDX Email Alerts:
